Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.
de Vries
H
H
Mulder
N H
NH
de Vries
E G
EG
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018273:Carcinoma, Islet Cell / Q000188:drug therapy* / Q000601:surgery; D016001:Confidence Intervals; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011788:Quality of Life; D012074:Remission Induction; D013311:Streptozocin / Q000008:administration & dosage*; D015996:Survival Rate
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D013311:Streptozocin; D004317:Doxorubicin